Skip to main content
. 2018 Feb 6;11(1):16. doi: 10.3390/ph11010016

Figure 3.

Figure 3

Survival proportions of NUC050, NUC052 and gemcitabine vs. saline control (SC) (n = 10 per group) in mice with human NSCLC NCI-H460 tumor implants. “Survival” refers to animals that were not removed from the study by death or per protocol euthanasia. Mice were administered the dose indicated IV qwk × 4 (study days 4–25) for NUC050. NUC052 was administered at 40 mg/kg IV qwk × 2 then 50 mg/kg IV × 2 (study days 4–25). Gemcitabine was administered IP at 120 mg/kg q3d × 4 and then 80 mg/kg IP q3d × 5 (study days 4–28). Median survival SC = 25.5 days. (1) NUC050 median survival = 33 days, hazard ratio (HR) vs. SC = 0.24 (p = 0.017, Log rank test). (2) NUC052 median survival = 34 days, HR = 0.27 (p = 0.033, Log rank test). (3) Gemcitabine median survival = 32.5 days, HR = 0.46 (p = 0.18, Log rank test).